Back to Search Start Over

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study.

Authors :
Rha, S.Y.
Wyrwicz, L.S.
Weber, P.E.Y.
Bai, Y.
Ryu, M.H.
Lee, J.
Rivera, F.
Alves, G.V.
Garrido, M.
Shiu, K-K.
Fernández, M. González
Li, J.
Lowery, M.
Cil, T.
Cruz, F.J.S.M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-Y.
Source :
Annals of Oncology. Mar2023, Vol. 34 Issue 3, p319-320. 2p.
Publication Year :
2023

Subjects

Subjects :
*ESOPHAGOGASTRIC junction
*PEMBROLIZUMAB
*CANCER chemotherapy

Details

Language :
English
ISSN :
09237534
Volume :
34
Issue :
3
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
161990541
Full Text :
https://doi.org/10.1016/j.annonc.2023.01.006
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details